Drug Pricing 2026: TrumpRx, PBM Shakeups, and the New Pharma Economics

The pharmaceutical industry is navigating its most significant pricing disruption in decades as administration drug pricing policies, pharmacy benefit manager transparency requirements, and accelerating retail pharmacy consolidation converge to reshape commercial economics. Traditional pricing and rebate strategies face new constraints as federal policy mandates greater transparency, PBM business models undergo forced evolution, and consolidated pharmacy networks gain negotiating leverage. The result is fundamental uncertainty about how drugs will be priced, distributed, and reimbursed - requiring pharma commercial teams to rethink market access strategies while protecting bottom-line revenue in a radically changed environment.

This meeting examines the confluence of policy, market forces, and consolidation trends that are rewriting pharmaceutical economics in 2026. The conversation will aim to decode how TrumpRx policies are impacting pricing flexibility and market access strategies, what PBM transparency rules mean for rebate negotiations and formulary positioning, and how pharmacy network consolidation is shifting power dynamics in specialty drug distribution. 

Join us to discuss:

• How are TrumpRx drug pricing policies and PBM transparency requirements forcing changes to pharma pricing strategies and rebate structures?

• What does pharmacy network consolidation mean for specialty drug distribution, patient access pathways, and pharma-pharmacy relationships?

• How can pharmaceutical companies adapt commercial strategies to protect margins while maintaining patient access in the new pricing and distribution landscape?